Bio Rad Laboratories

BIO · NYSE

$354.50+$1.68 (+0.48%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $352.82

BIO analyst rating

HoldConsensus of 5 analysts over the last 12 months. 20% rate it a buy.

Strong buy0
Buy1
Hold4
Underperform0
Sell0

12-month price target · 4 analysts

Average $359.55 (+1.4% upside)

Low: $318.15
Now: $354.50
High: $409.50

Upgrades and downgrades

The latest rating actions, newest first

BIO analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
RBC Capital	Aug 7, 2026	Maintains	Outperform	$370.00 → $390.00	59%
Citigroup	Aug 5, 2026	Maintains	Neutral	$300.00 → $330.00	44%
RBC Capital	Aug 5, 2026	Maintains	Outperform	$320.00 → $370.00	59%
Wells Fargo	Aug 5, 2026	Maintains	Equal-Weight	$310.00 → $330.00	100%
RBC Capital	May 15, 2026	Initiates	Outperform	$320.00	59%
Wells Fargo	May 1, 2026	Maintains	Equal-Weight	$320.00 → $290.00	66%
Citigroup	Apr 7, 2026	Downgrade	Buy → Neutral	$375.00 → $300.00	55%
Wells Fargo	Feb 16, 2026	Maintains	Equal-Weight	$340.00 → $320.00	66%
Citigroup	Oct 30, 2025	Maintains	Buy	$350.00 → $375.00	55%
Wells Fargo	Oct 30, 2025	Maintains	Equal-Weight	$265.00 → $340.00	66%

The case for and against

Updated Oct 18, 2026

Bull case

Bio-Rad Laboratories is viewed positively because management is signaling a meaningful retooling of the business, with a mid-teens EBIT margin objective versus the 11% guided midpoint for 2026 and a systematic restructuring that began in late 2025 across commercial, operating, and earlier R&D expenses. Investors also see improving fundamentals as Q2 helped de-risk the 2H ramp, end markets are stabilizing, and product pressures in process chromatography are expected to ease, supporting faster sales growth when headwinds lapse. Additional upside comes from the company’s ~33% stake in Sartorius, whose optionality should increase in mid-2028 when the controlling Trust terminates, while Bio-Rad’s core diagnostics and life sciences franchises remain well positioned across global markets.

Bear case

Bio-Rad Laboratories is facing a negative outlook because its life science tools business still depends on an end-market recovery that has taken years to normalize and may not arrive, while its ddPCR franchise has been losing share to Qiagen over the past several years. The company also carries structural risk from a business mix exposed to wet-lab research, potential AI-driven shifts away from that work, and a mixed M&A record that heightens execution risk. On top of that, further multiple erosion and a steeper discount to the Sartorius stake could reflect fading investor confidence in sales and margin trajectory, while dual-class governance concentrates control with the Schwartz family and may not align with broader shareholders.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.